Health Care • Biotechnology: Pharmaceutical Preparations
$9.33 ▲ +0.18
(+1.97%)
MKT CAP: $351.0M • VOL: 566.9K
52W L $7 52W H $18
ROARABLE / RQD
D- • 40/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$8
MEDIAN
$10
MEAN
$11
HIGH
$13
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE CTNM TAPE
CTNM // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $11.29 | $10.73 | 2025-02-14 | $8.49 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $11.76 | $11.01 | 2025-02-06 | $8.77 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $10.64 | $10.26 | 2025-01-29 | $8.96 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $9.52 | — | 2025-01-17 | $9.14 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $8.21 | $8.86 | 2025-01-09 | $8.30 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $11.10 | $9.70 | 2024-12-18 | $8.12 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $9.05 | $9.42 | 2024-12-04 | $8.68 | -4.3% | 48% | C |